title: [The effects of gastrojejunostomy for patients with advanced gastric cancer accompanied by peritoneal dissemination].
abstract: We evaluated the efficacy of gastrojejunostomy for advanced gastric cancer patients with peritoneal dissemination.
  
  
  METHODS
  We evaluated the clinical outcome of 11 patients (average age 73.5 years for 8 men) who received gastrojejunostomy for gastric outlet obstruction caused by advanced gastric cancer with peritoneal dissemination between October 2003 and December 2008. We performed stomach-partitioning gastrojejunistomy with tube jejunostomy.
  
  
  RESULTS
  Three patients with performance status 3 and severe peritoneal dissemination deteriorated during the early postoperative days and were transferred to terminal care. These three patients died after 23, 26 and 60 days. The other 8 patients were discharged from hospital between 10 and 35 days postoperatively (median hospital stay 16 days) and received chemotherapy with S-1 on an outpatient basis. All patients died within one year except the one who showed a partial response to chemotherapy and lived for 40 months (MST: 8 months in all patients).
  
  
  CONCLUSIONS
  It seemed that there was little adaptation to gastrogejunostomy as palliation surgery for patients with poor performance status (PS 3) and severe peritoneal dissemination.
authors.affiliation: Dept. of Surgery, Kansai Rosai Hospital.
authors.forename: Shigeyuki
authors.initials: S
authors.lastname: Tamura
authors.forename: Atsushi
authors.initials: A
authors.lastname: Takeno
authors.forename: Hirofumi
authors.initials: H
authors.lastname: Miki
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Kanemura
authors.forename: Ayako
authors.initials: A
authors.lastname: Yanai
authors.forename: Masayoshi
authors.initials: M
authors.lastname: Kobayashi
authors.forename: Yasumasa
authors.initials: Y
authors.lastname: Yoshioka
authors.forename: Rei
authors.initials: R
authors.lastname: Suzuki
authors.forename: Shin
authors.initials: S
authors.lastname: Nakahira
authors.forename: Chiyomi
authors.initials: C
authors.lastname: Egawa
authors.forename: Ken
authors.initials: K
authors.lastname: Nakata
authors.forename: Shu
authors.initials: S
authors.lastname: Okamura
authors.forename: Keishi
authors.initials: K
authors.lastname: Sugimoto
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Takatsuka
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D004338:Drug Combinations; D005260:Female; D015390:Gastric Bypass; D017219:Gastric Outlet Obstruction / Q000601:surgery; D006801:Humans; D008297:Male; D008875:Middle Aged; D010094:Oxonic Acid / Q000627:therapeutic use; D010166:Palliative Care; D010534:Peritoneal Neoplasms / Q000556:secondary*; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery*; D005641:Tegafur / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid